Home・Akciju saraksts・Vericel Corp

Vericel Corp

Atvērts

SektorsVeselības aprūpe

43.99 -1.1

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

43.27

Max

44.91

Galvenie mērījumi
By Trading Economics
Ienākumi	13M 6.3M
Pārdošana	9M 77M
P/E Sektora vidējais	93.511 57.002
EPS	0.04
Peļņas marža	8.136
Darbinieki	398
EBITDA	8.5M 5.6M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt (spēcīgs)
Prognoze 12 mēnešiem	+38.08% upside

Dividendes
By Acuity
Nākamie ieņēmumi	2026. g. 5. nov.

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	-64M 2.3B
Iepriekšējā atvēršanas cena	45.09
Iepriekšējā slēgšanas cena	43.99

Ziņu noskaņojums

By Acuity

100%

325 / 340 Rangs Healthcare

Vericel Corp Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 13. aug. 19:43 UTC

Vericel Corp shares are lower today, reflecting ongoing weakness below the 20-day moving average and near the lower end of their one-month range.

2026. g. 11. aug. 19:46 UTC

News

Vericel Corp shares are higher as analysts maintain a "Moderate Buy" consensus, with HC Wainwright's target at $70 and Truist raising its target to $58.

2026. g. 10. aug. 19:46 UTC

Correlated Moves

Vericel Corp shares are lower today, reflecting a broader market decline and volatility amid uncertainty over the Federal Reserve's interest rate policy.

2026. g. 7. aug. 19:16 UTC

Correlated Moves

Vericel Corp's shares rise, supported by gains in the ARK Genomic Revolution ETF and Russell 2000 Index, despite earlier fluctuations in trading.

2026. g. 6. aug. 19:26 UTC

Correlated Moves

Vericel Corp shares declined during Thursday's session, tracking broader market trends. The stock remains near the lower end of its one-month trading range.

2026. g. 5. aug. 19:26 UTC

Correlated Moves

Vericel Corp shares are lower today, reflecting broader market trends as the Russell 2000 Index declines. The stock remains below its 20-day moving average.

2026. g. 3. aug. 20:03 UTC

Correlated Moves

Vericel Corp shares are advancing, supported by significant gains in the broader market and major tech stocks, contributing to positive investor sentiment.

2026. g. 31. jūl. 20:02 UTC

Correlated Moves

Vericel Corp's price is lower today, influenced by declines in the Biotechnology sub-sector and a falling Russell 2000 Index.

2026. g. 30. jūl. 20:36 UTC

Correlated Moves

Vericel Corp shares gained in after-market trading, aligning with a rising Russell 2000 Index. The stock remains above its 20-day moving average.

2026. g. 29. jūl. 19:27 UTC

Correlated Moves

Vericel Corp shares declined during Wednesday's session, continuing a downward trend since Tuesday's close, amid broader market weakness reflected in the Russell 2000 Index.

2026. g. 28. jūl. 21:02 UTC

Vericel Corp shares are lower in after-market trading, reflecting broader market caution amid declines in the Nikkei 225 Index and technology sector concerns.

2026. g. 27. jūl. 20:31 UTC

Vericel Corp shares declined during after-market hours amid unusual selling pressure. The stock remains below its 20-day moving average with no specific news identified.

2026. g. 24. jūl. 19:46 UTC

Correlated Moves

Vericel Corp reported first-quarter revenue of $39.2 million, missing estimates. Shares are lower amid broader market declines affecting small-cap biotechnology stocks.

2026. g. 22. jūl. 20:13 UTC

Vericel Corp shares are trading higher in after-market hours, influenced by broader market volatility amid rising crude oil prices and geopolitical tensions.

2026. g. 21. jūl. 14:31 UTC

Vericel Corp shares are higher, supported by overall market momentum and a recovery in Asian markets, particularly the Nikkei 225 Index.

2026. g. 20. jūl. 17:46 UTC

Correlated Moves

Vericel Corp shares are lower today, aligning with a decline in the ARK Genomic Revolution ETF and the Russell 2000 Index.

Salīdzinājums

Cenas izmaiņa

Vericel Corp Prognoze

Cenas mērķis

By TipRanks

38.08% augšup

Prognoze 12 mēnešiem

Vidējais 61.5 USD 38.08%

Augstākais 72 USD

Zemākais 58 USD

Pamatojoties uz 4 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Vericel Corp — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

4 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 4 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Vericel Corp — pēdējo 3 mēnešu laikā.

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Vericel Corp

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.